The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review …
ML O'Donoghue, SA Murphy, MS Sabatine - Circulation, 2020 - Am Heart Assoc
Background: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients after Percutaneous Coronary Intervention: A Systematic Review …
ML O'Donoghue, SA Murphy, MS Sabatine - isoic.org
Background: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review …
ML O'Donoghue, SA Murphy, MS Sabatine - Circulation, 2020 - europepmc.org
Background Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review …
ML O'Donoghue, SA Murphy, MS Sabatine - Circulation, 2020 - pubmed.ncbi.nlm.nih.gov
Background Dual antiplatelet therapy with aspirin and a P2Y 12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Circulation, 2020 - Am Heart Assoc
BACKGROUND: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been
shown to reduce the risk of major adverse cardiovascular events (MACE) compared with …
shown to reduce the risk of major adverse cardiovascular events (MACE) compared with …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y 12 Inhibitor in Patients After Percutaneous Coronary Intervention
ML O'Donoghue, SA Murphy, MS Sabatine - Circulation, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Background:</jats: title>< jats: p> Dual antiplatelet therapy with
aspirin and a P2Y< jats: sub> 12</jats: sub> inhibitor has been shown to reduce the risk of …
aspirin and a P2Y< jats: sub> 12</jats: sub> inhibitor has been shown to reduce the risk of …
The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients After Percutaneous Coronary Intervention: A Systematic Review …
ML O'Donoghue, SA Murphy, MS Sabatine - Circulation, 2020 - ingentaconnect.com
Background: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been shown to
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
reduce the risk of major adverse cardiovascular events (MACE) compared with aspirin alone …
[PDF][PDF] The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y
Circulation, 2020 - isoic.org
BACKGROUND: Dual antiplatelet therapy with aspirin and a P2Y12 inhibitor has been
shown to reduce the risk of major adverse cardiovascular events (MACE) compared with …
shown to reduce the risk of major adverse cardiovascular events (MACE) compared with …